Protein SIC secreted from Streptococcus pyogenes forms complexes with extracellular histones that boost cytokine production

Westman, Johannes; Chakrakodi, Bhavya; Snäll, Johanna; Mörgelin, Matthias; Madsen, Martin Bruun; Hyldegaard, Ole; Neumann, Ariane; Frick, Inga Maria; Norrby-Teglund, Anna; Björck, Lars; Herwald, Heiko

Published in:
Frontiers in Immunology

DOI:
10.3389/fimmu.2018.00236

Publication date:
2018

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Westman, J., Chakrakodi, B., Snäll, J., Mörgelin, M., Madsen, M. B., Hyldegaard, O., ... Herwald, H. (2018). Protein SIC secreted from Streptococcus pyogenes forms complexes with extracellular histones that boost cytokine production. Frontiers in Immunology, 9, [236]. https://doi.org/10.3389/fimmu.2018.00236

Download date: 05. Mar. 2020
Innate immunity relies on an effective recognition of the pathogenic microorganism as well as on endogenous danger signals. While bacteria in concert with their secreted virulence factors can cause a number of inflammatory reactions, danger signals released at the site of infection may in addition determine the amplitude of such responses and influence the outcome of the disease. Here, we report that protein SIC, Streptococcal Inhibitor of Complement, an abundant secreted protein from *Streptococcus pyogenes*, binds to extracellular histones, a group of danger signals released during necrotizing tissue damage. This interaction leads to the formation of large aggregates *in vitro*. Extracellular histones and SIC are abundantly expressed and seen colocalized in biopsies from patients with necrotizing soft-tissue infections caused by *S. pyogenes*. In addition, binding of SIC to histones neutralized their antimicrobial activity. Likewise, the ability of histones to induce hemolysis was inhibited in the presence of SIC. However, when added to whole blood, SIC was not able to block the pro-inflammatory effect of histones. Instead SIC boosted the histone-triggered release of a broad range of cytokines and chemokines, including IL-6, TNF-α, IL-8, IL-1β, IL-1ra, G-CSF, and IFN-γ. These results demonstrate that the interaction between SIC and histones has multiple effects on the host response to *S. pyogenes* infection.

**Keywords:** extracellular histones, streptococcal inhibitor of complement, toll-like receptor, antimicrobial peptide, cytokines, *Streptococcus pyogenes*, innate immunity

**INTRODUCTION**

*Streptococcus pyogenes* (group A streptococcus, GAS) is an important human pathogen that may cause a number of conditions from harmless throat infections to invasive diseases such as septicemia, necrotizing soft-tissue infections (NSTI), and streptococcal toxic shock syndrome (1). The innate immune system is the first response to *S. pyogenes* infections. To counteract this and
maintain colonization, *S. pyogenes* is equipped with an arsenal of virulence factors (for an excellent review, see Ref (2)). One of these is protein SIC (Streptococcal Inhibitor of Complement). SIC is a highly polymorphic 31 kDa negatively charged protein that is secreted by only a few M serotypes including M1, M12, M55, and M57. Originally, SIC was described to interfere with complement function (3, 4), but the last decade has demonstrated that it exerts multifunctional activities and binds to several different ligands (5–9). Perhaps most importantly SIC blocks the cytolytic activity of several antimicrobial peptides (AMPs) such as LL-37, defensins, H-kininogens, H-kininogen-derived peptides, and lysozyme (5–9). The binding of SIC to cationic AMPs is mediated by the negative charge of the streptococcal protein. It has been reported that upon binding to SIC, AMPs lose their cytolytic activity (6, 7). This is considered as an important mechanism for host colonization as it prevents bacterial degradation. Besides interfering with AMPs and complement function, SIC also blocks contact activation, prolongs blood clotting, and inhibits the release of bradykinin, a potent vasodilator (10). The *sic* gene is regulated by the multiple gene regulator of GAS (mga) (11). Mga is a DNA-binding protein that activates genes important for invasion. Apart from SIC, mga also induces transcription of genes coding for proteins involved in adherence, internalization, and immune evasion (11).

Previous *in vitro* studies have shown that SIC can be considered as an anti-inflammatory and anti-cytolytic agent (3, 4, 6–10, 12). In addition, *in vivo* experiments in mice have demonstrated that a SIC-mutant strain is less virulent than a wild-type strain expressing SIC (7). During deep tissue infections such as NSTI, neutrophils are recruited to the site of infection where they degranulate and release their nuclear content also referred to as neutrophil extracellular traps (13). Neutrophil extracellular traps consist of DNA and proteins of which the majority are histones (14). It was recently reported that the released histones contribute to bacterial killing and exerts immunomodulatory functions such as the induction of cytokine/chemokine production (15–18). Thus, extracellular histones act as danger signals, alerting the innate immunity of the intruder by interacting with toll-like receptors (TLRs). Besides cytokine/chemokine production, histones can cause platelet aggregation through forming complexes with fibrinogen, thrombin generation, NLRP3 inflammasome activation, and trigger lysis of host cells and erythrocytes (17–21). How histones exert their antimicrobial activity is not completely understood. However, Hirsch (22) described how histones adsorbed microbes in a pH-dependent manner. Histones are cationic in their amino-terminal portion and neutrally charged in their carboxy termini. While the cationicity in histone H1 is predominantly constituted by lysine, the cationic charge of histone H2A, H2B, H3, and H4 is mediated by lysines and arginines. It is therefore tempting to speculate that histones could interact with SIC in a charge-dependent fashion. However, additional studies are required to unravel this issue.

Natural infections with *S. pyogenes* only occur in humans, and in the present work we investigate the immunomodulatory properties of SIC in human blood. Here, we demonstrate that SIC has multiple effects on the host response. First, this paper describes the biochemical properties of SIC/histone interactions and then continues with its functional effects on the innate immune system. We find that besides inhibiting the bacterial activity of extracellular histones, SIC forms complexes with histones *in vitro* and colocalizes in patients with NSTI. Furthermore, our data show that SIC/histone complexes induce a broad pathological pro-inflammatory cytokine response in human blood.

**MATERIALS AND METHODS**

**Patient Material**

Tissue biopsies were collected from patients with NSTI enrolled at Rigshospitalet, Copenhagen, Denmark, as part of the EU-funded project INFECT during 2013–2014 (ClinicalTrials.gov Identifier: NCT01790698). Also included were biopsies of healthy skin tissue obtained at plastic surgery at Karolinska University Hospital, Stockholm, Sweden. The studies were conducted in accordance with the Helsinki Declaration and approved by the regional Ethical Review Board at the Regional Ethics committee in Stockholm as well as by the National Committee on Health Research Ethics in Copenhagen. Written informed consent was obtained from all patients or their legal surrogates.

**Proteins and Antibodies**

Histone H1, H2A, H2B, H3.1, and H4 were purchased from Bionordika (Stockholm, Sweden) and calf thymus histones (histones) from Roche (Basel, Switzerland). [Histone H4-derived peptides were synthesized at Biopeptide Co. (San Diego, CA, USA).] Peroxidase-conjugated goat anti-rabbit and goat anti-mouse immunoglobulin G were from Bio-Rad Laboratories (Berkley, CA, USA). Antibodies against histone H4 (polyclonal chip-grade anti-histone H4) were from Abcam (Cambridge, UK). Rat polyclonal antibodies to human TLR4, TLR2 and isotype control and the TLR4-inhibitor CLI-095 were purchased from InvivoGen (San Diego, CA, USA).

**Bacterial Strains and Protein Purification**

The *S. pyogenes* strain AP1 (M1 serotype) was from World Health Organization Collaborating Center for Reference and Research on Streptococci, Prague, Czech Republic. SIC was purified from *S. pyogenes* AP1 strain culture medium as described by Åkesson et al. (3) by precipitation of the bacterial supernatant (SN) with 30% ammonium sulfate, followed by ion-exchange chromatography on a Mono Q column. SIC fractions were dialyzed against 20-mM Tris–HCl pH 7.5 and analyzed using SDS-PAGE. The SIC-mutant strain was generated as described by Frick et al. (7). The SIC preparation used in this study was analyzed by shot-gun mass spectrometry. No other streptococcal proteins were detected and the only contamination found were traces of human keratin. Antiserum against SIC and isotype control serum were raised in rabbits. SIC was labeled with 125I using Pierce IODO. BEADS® Iodination reagent (Thermo Scientific, Waltham, MA, USA). Molarity calculation of SIC was based on a molecular weight of 31,000 Da.
**Blood Collection**

Blood was drawn from healthy donors into 6.0-mL sodium heparin tubes (Becton Dickinson, Franklin Lakes, NJ, USA) or into 2.7-mL 0.109-M sodium citrate tubes (Becton Dickinson, Franklin Lakes, NJ, USA). Blood samples were stored at room temperature for 30 min before usage.

**SIC Precipitation, SDS-PAGE, and Western Blotting**

*Streptococcus pyogenes* AP1 bacteria and SIC-mutant bacteria were grown for 9 h in Todd–Hewitt (TH) broth at 37°C. After 6 h, the bacteria were centrifuged at 2,000×g and the SNs were sterile filtered. SNs (1 mL) from SIC-producing AP1 and the SIC knockout were mixed with 250 µL of 100% trichloroacetic acid. Samples were incubated for 10 min at 4°C. All samples were centrifuged at 18,000×g for 5 min. The SN was removed from the white pellet in bottom of every test tube. Pellets were dissolved in 200 µL ice-cold 100% acetone. All samples were centrifuged again at 14,000 rpm for 5 min. SN was removed and the pellet was dried at 95°C in a heat block for 10 min. Each pellet was dissolved in sample buffer (Bio-Rad Laboratories, Berkeley, CA, USA) and boiled for 10 min at 95°C. Samples were loaded into a 10% PAGE gel as described by Laemmli (23). Proteins were transferred onto a polyvinylidene difluoride membrane (GE Healthcare, Uppsala, Sweden), blocked with 5% non-fat milk powder in 10-mM PBS, 0.05% Tween-20 (PBS-T), incubated with primary rabbit anti-SIC serum (1:1,000), and secondary peroxidase-labeled goat anti-mouse IgG (1:3,000, Bio-Rad Laboratories, Berkley, CA, USA). All incubation steps were performed at RT for 60 min on rotation and were followed by three washing steps in PBS-T. The polyvinylidene difluoride membrane was developed using SuperSignal West Pico Chemiluminescence kit (Thermo Scientific, Waltham, MA, USA) according to manufacturer’s instructions.

**Slot Blot**

A polyvinylidene difluoride filter (Millipore, Billerica, MA, USA) was activated in methanol, washed in destilled water, and exposed to different histones subtypes in three different concentrations using a Milliblot-D system (Millipore, Billerica, MA, USA). The filter was washed with 100-µL PBS, blocked with 5% non-fat milk powder in PBS and probed with 125I-labeled SIC (2 × 104 cpm/mL) for 3 h in RT. The filter was washed three times for 20 min with PBS-T and autoradiography was carried out using Kodak x-Omat AR films and regular intensifying screens.

**Peptide ELISA**

Microtiter plates were coated overnight with 100 µL histone H4-derived peptides (1 µM) in coating buffer (15.9-mM Na2CO3, 30-mM NaHCO3, pH 9.6) at 4°C. The next day, plates were washed three times in PBS containing 0.05% Tween-20 (PBST) and blocked in PBST containing 0.5% bovine serum albumin for 60 min at 37°C. After blocking and another washing step, plates were probed with 100 µL SIC (40 nM) for 1 h at 37°C and binding was detected with 100 µL rabbit SIC antiserum (1:2,000) followed by 100 µL of a peroxidase-conjugated antibody against rabbit IgG (1:3,000, Bio-Rad Laboratories, Berkeley, CA, USA). Stabilized tetramethylbenzidine Chromogen (Thermo Fisher Scientific, Waltham, MA, USA) was used as a substrate for the peroxidase-conjugated antibody. The reaction was terminated with 10% H2SO4 and measured at 450 nm for 0.1 s per measured well.

**Surface Plasmon Resonance**

All analyses were performed using a BIAcore X100 instrument (GE Healthcare, Uppsala, Sweden). Histone H4 was diluted in sodium acetate (10 mM, pH 5.5) and immobilized to a Sensor Chip CM5 via amine coupling to flow cell 2. Flow cell 1 was immobilized without protein and was used as a control for each experiment. SIC (400–25 nM) was injected in a flow (30 µL/min) over the Sensor Chip in HBS-EP buffer [10-mM HEPES, 150-mM NaCl, 3-mM EDTA, 0.05% (v/v) Surfactant P20, pH 7.4]. Regeneration of the Sensor Chip was obtained by injection of 30 µL 50-mM NaOH. All experiments were run at 25°C in degassed buffers. Affinity constants were calculated using BIAevaluation software (GE Healthcare, Uppsala, Sweden).

**Negative Staining and Transmission Electron Microscopy**

Binding between SIC and histone H4 was visualized using negative staining and electron microscopy as previously described (24). Histone H4 was conjugated with 10-nm colloidal gold particles according to routine protocols (25). Conjugates were incubated with each other for 30 min at RT and negatively stained with 0.75% uranyl formate. Specimens were examined in a Philips/FEI CM100 BioTwin transmission electron microscope at a 100,000× magnification.

**Bacterial Viable Count Assay**

*Streptococcus pyogenes* AP1 strain and the SIC-mutant *S. pyogenes* strain were plated overnight at 37°C on blood agar plates and stored at 4°C. For each experiment, colonies from the blood agar plate were added to 10 mL in TH broth (Sigma-Aldrich, St. Louis, MO, USA) and incubated at 37°C overnight. SIC mutant was grown in TH broth containing 0.15-mg/mL Kanamycin. The following day, the bacteria were mixed and 200 µL were transferred to 10-mL fresh TH broth and incubated to reach logarithmic phase (OD620nm, 0.4) at 37°C. The bacteria were centrifuged at 2,000×g and washed in ice cold 10-mM PBS with 5-mM glucose (PBS-G). Bacteria were diluted to 2 × 1010 colony-forming units (CFUs)/mL in PBS-G. Histones (5 µg/mL) or histone H4 (0.36 µM), with or without increasing concentrations of SIC (0.16, 0.32, or 0.64 µM), were preincubated for 30 min at 37°C in a total volume of 50 µL. The same volume of diluted bacteria was added to each sample, and the samples were incubated for 60 min at 37°C with 5% CO2. All samples were diluted in PBS-G and plated on TH agar plates overnight at 37°C. The following day, colonies were manually counted and the number of viable CFUs was described as a ratio of viable colonies compared with non-stimulated bacteria.

**Hemolysis Assay**

Citrated blood (1 mL) was centrifuged at 2,000×g for 10 min to pellet cells. The blood plasma was discarded and replaced by
Cytokine Production in Blood

Histones (50 µg/mL), LL-37 (25 µg/mL), β-defensin-3 (25 µg/mL), high-mobility group box 1 (HMGB1, 25 µg/mL), heparin-binding protein (HBP, 25 µg/mL), SIC (0.64 µM), or the AMPs in combination with different SIC concentrations were incubated with heparinized blood diluted 1:1 in PBS for 7 h at 37°C on rotation. For inhibition experiments, antibodies against human TLR4 (25 µg/mL), human TLR2 (25 µg/mL), isotype control (25 µg/mL), or the TLR4 inhibitor CLI-095 (1–10 µg/mL) were added simultaneously to histones and SIC. Blood aliquots were removed at different time points and centrifuged at 2,000×g for 10 min. The plasma SN was removed and frozen at −20°C. IL-6 was measured in heparin plasma SN using Human IL-6 Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA) using the manufacturer’s instructions. Samples were discarded after the IL-6 measurements and were not repeatedly frozen.

Immunostaining of Tissue Biopsies

Snap-frozen tissue biopsies from healthy controls or from patients with NSTI caused by M1 or M3 S. pyogenes strains were analyzed. The biopsies were cryosectioned to 8 µm and fixed in ice-cold acetone or 2% formaldehyde for immunofluorescent or immunohistochemical stainings, respectively. Stainings were performed in singlets on consecutive sections as described previously (16, 17, 26, 27). The following antibodies were used at predetermined optimal concentrations: mouse monoclonal anti-histone H4 (Abcam, Cambridge, UK), rabbit anti-SIC serum, goat polyclonal anti-Lancefield group A carbohydrate (Abcam, Cambridge, UK), and rabbit polyclonal antibodies against human HMGB1 (Abcam, Cambridge, UK) and human IL-8/NAP-1 (Invitrogen, Waltham, MA, USA). Biotinylated secondary antibodies included rabbit-anti-goat IgG and goat-anti-rabbit IgG (both from Vector Laboratories, Burlingame, CA, USA). For fluorescence stainings, Alexa 546 conjugated donkey anti-rabbit IgG and Alexa 488 conjugated donkey anti-mouse IgG (both from Molecular Probes, Eugene, OR, USA) were used. Slides were mounted using DAPI-supplemented mounting media (Molecular Probes, Eugene, OR, USA). Single stainings were performed to assure specificity of staining patterns. For image evaluation, a Nikon A1R confocal microscope was used (Nikon Instruments, Amstelveen, the Netherlands). The immunohistochemically stained sections were analyzed by acquired computerized image analysis (ACIA) as previously described (28). The cell area was defined by the hematoxylin counterstaining and the results are presented as ACIA values, which equal the percentage of positively stained area × mean intensity of positive staining.

Multiplex Cytokine Quantification Assay

The cytokine analysis was performed using a Bio-Plex 200 instrument and a Bio-Plex Pro Human Cytokine 27-Plex Assay (both from Bio-Rad Laboratories, Berkeley, CA, USA) FGF basic, Eotaxin, G-CSF, GM-CSF, IFN-γ, IL-1β, IL-1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-10, IL-12, IL-13, IL-15, IL-17, CXCL10, CCL2, CCL3, CCL4, PDGF-bb, RANTES, TNF-α, and VEGF. The cytokine panel was designed to provide a measure of cytokines, chemokines, and growth factors. All samples, standards, and controls were run in duplicates and data was acquired using Bio-Plex Manager Software (version 6.1).

Statistical Analyses

Data were analyzed using GraphPad Prism 7 (GraphPad Software, San Diego, CA, USA). One-way ANOVA with Dunnett’s or Tukey’s test was used to determine significance between multiple comparisons.

RESULTS

Expression of SIC and Binding of SIC to Extracellular Histones

Before investigating the interaction between SIC and histones, the production of the streptococcal protein in the strains employed in this study was determined. The S. pyogenes isolates AP1 (wild-type) and the isogenic S. pyogenes-mutant strain-lacking SIC (SIC-mutant) were used throughout this study. The SNs from both bacterial strains were collected at 6 h, precipitated with trichloroacetic acid, and SIC was visualized using SDS-PAGE (Figure 1A; Figure S1A in Supplementary Material) followed by Western blot analysis using antisera against SIC (Figure 1B; Figure S1B in Supplementary Material). The results show that SIC is secreted from the wild-type, but not expressed in the SIC-mutant strain, and they also reveal that SIC is the most abundant protein secreted from S. pyogenes under these culture conditions (Figure 1A). No SIC expression was detected when the mutant strain was analyzed (Figures 1A,B).

Previous work has shown that SIC is highly anionic and interacts with a number of different AMPs (5–7). As extracellular histones are, like AMPs, positively charged, we sought to study a possible interaction between SIC and histones. The five different histone subtypes were immobilized in different concentrations on an Immobilon filter and probed with 125I-labeled SIC. The slot blot depicted that SIC interacts with histones H3 and H4 but not with histones H1, H2A, or H2B (Figure 1C). Histone H4 is highly cationic (net charge +19) and it was recently described to trigger a number of pathological reactions such as the aggregation of platelets, hemolysis of erythrocytes, and the production of chemokines under in vitro and in vivo conditions (15–19, 29). Based on these results, we decided to focus on histone H4 in subsequent experiments. To this end, we first confirmed the interaction between SIC and histone H4 using Surface Plasmon Resonance technology. These experiments revealed that SIC and histone H4 associate rapidly followed by a slow dissociation phase, resulting in an affinity constant which was in the lower nanomolar range (Table 1 and Figure 1D). To map the SIC/histone H4 interaction
FIGURE 1 | Streptococcal inhibitor of complement (SIC) expression and its binding to histones. (A) S. pyogenes wild-type and SIC-mutant SNs were precipitated with trichloroacetic acid and separated on a 10% SDS-PAGE. (B) SIC was identified in SNs using rabbit antisera against SIC. (C) An Immobilon filter was immobilized with different histone subtypes, incubated with 125I-labeled SIC and bound probe was detected with the Fuji FLA-3000 imaging system. (D) SPR technology was used to show the interaction between histone H4 and SIC. Histone H4 was coated on a CM5 Sensor Chip and SIC was applied in a flow at different concentrations. (E) Microtiter plates were coated with histone H4-derived peptides and probed with SIC. Binding was detected using rabbit antisera against SIC and visualized by a peroxidase-conjugated secondary antibody. Data show means ± SEM (one-way ANOVA, Tukey’s test). All experiments were independently performed at least three times and one representative image is shown. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.

TABLE 1 | Affinity constants for the binding of SIC to histone H4.

| Sample      | $k_a/(1/M_s)$ | $k_d/(1/s)$ | $K_D(M)$  |
|-------------|---------------|-------------|-----------|
| Protein SIC | 3.347 x 10^4  | 5.908 x 10^-4 | 1.765 x 10^-8 |

Histone H4 was immobilized to a Biacore CM5 Sensor Chip and different concentrations of SIC were applied in a flow. Affinity constants for SIC/histone H4 binding were determined using BIAevaluation software (GE Healthcare, Uppsala, Sweden).

S. pyogenes M1 strains, and that the protein specifically interacts with histones H3 and H4, but not with histones H1, H2A, and H2B, respectively. Moreover, we found that SIC binds to the N-terminal part of histone H4, which is the most cationic part of the protein, and can form complexes with up to two histone molecules simultaneously.

SIC Interfering with Antimicrobial and Hemolytic Activity of Extracellular Histones

Extracellular histones and other AMPs are potent killers of a broad range of bacterial pathogens (22, 30, 31). To
counteract a cytotoxic attack by such substances, *S. pyogenes* has developed several strategies to cope with these host responses, including the secretion of SIC. It was previously reported that SIC inhibits the bactericidal activity of LL-37 (7) and several defensins (5, 7) and it also interferes with the contact and complement systems (6, 10). In the case of AMPs, it has been reported that SIC prevents their interaction with the bacterial membrane (3–10). Based on these findings, we sought to determine whether SIC interferes with the bactericidal activity of histones. To investigate the effect of SIC on histones, we performed viable count assays. Wild-type bacteria were grown to log-phase, extensively washed, and diluted to enable determination of viability by measuring CFUs. As the washing steps let to a depletion of endogenously produced SIC, resuspended bacteria were reconstituted with SIC purified from the wild-type SN. Reconstituted and non-reconstituted wild-type *S. pyogenes* bacteria were incubated with histones or histone H4. After 60-min incubation, bacteria were plated and enumerated the next day to determine the viability. Addition of SIC rescued bacteria in a dose-dependent manner against histones (Figure 3A) and histone H4 (Figure 3B) and similar results were obtained when the SIC mutant was analyzed (Figure 3C). Besides perforating bacterial membranes, extracellular histones can lyse eukaryotic cells including erythrocytes and thereby cause hemolysis, a common characteristic of systemic inflammatory response syndromes (17). To investigate if SIC can block the cytolytic activity of histones, we wished to investigate whether it also inhibits histone-induced release of these inflammatory mediators. Using Bioplex multiplex assays, blood from healthy donors were incubated with histones in the absence or presence of SIC and a panel of 27 cytokines, chemokines, and growth factors were measured. Under these experimental conditions, histones alone acted often as weak or moderate inducers of cytokines/chemokines (Figure 4). However, histones in complex with SIC boosted the pro-inflammatory response, yielding a robust increase in cytokines/chemokines such as TNF-α (Figure 4A), IL-8 (Figure 4B), IL-1β (Figure 4C), IL-1ra (Figure 4D), G-CSF (Figure 4E), IFN-γ (Figure 4F), and IL-6 (Figures 5A,B). SIC alone had no effect on the induction of these proteins except for one donor. Interestingly, the coinubation with SIC did not always boost the inflammatory response. For example, histone-induced PDGF-bb expression was to some extent blocked by SIC (Figure 4G) and SIC did not affect histone-induced CXCL10 production (Figure 4H). Furthermore, a broad range of cytokines were not affected by either histones or SIC, or not significantly elevated (Figure S3 in Supplementary Material). This shows that SIC together with histones induced a potential pathological response of a broad range of cytokines and chemokines.

**sic/histone complexes Triggering the Induction of Multiple Cytokines and Chemokines**

Extracellular histones were recently described to act as danger-associated molecular patterns (or danger signals) as they can induce cytokine (15) and chemokine production (16) and trigger leukocyte migration *in vivo* (16). Cytokines such as TNF-α, IL-6, IL-8, CXCL10, and IFN-γ are released upon histone stimulation, and it has been reported that their release is dependent on different TLRs (15, 16, 20, 21). As our data demonstrated that SIC can block the cytolitic activity of histones, we wished to investigate whether it also inhibits histone-induced release of these inflammatory mediators. Using Bioplex multiplex assays, blood from healthy donors were incubated with histones in the absence or presence of SIC and a panel of 27 cytokines, chemokines, and growth factors were measured. Under these experimental conditions, histones alone acted often as weak or moderate inducers of cytokines/chemokines (Figure 4). However, histones in complex with SIC boosted the pro-inflammatory response, yielding a robust increase in cytokines/chemokines such as TNF-α (Figure 4A), IL-8 (Figure 4B), IL-1β (Figure 4C), IL-1ra (Figure 4D), G-CSF (Figure 4E), IFN-γ (Figure 4F), and IL-6 (Figures 5A,B). SIC alone had no effect on the induction of these proteins except for one donor. Interestingly, the coinubation with SIC did not always boost the inflammatory response. For example, histone-induced PDGF-bb expression was to some extent blocked by SIC (Figure 4G) and SIC did not affect histone-induced CXCL10 production (Figure 4H). Furthermore, a broad range of cytokines were not affected by either histones or SIC, or not significantly elevated (Figure S3 in Supplementary Material). This shows that SIC together with histones induced a potential pathological response of a broad range of cytokines and chemokines.
Fig. 3 | SIC inhibiting the cytolytic activity of histones. S. pyogenes wild-type were grown to mid-log phase, washed, and diluted to $2 \times 10^6$ CFU/mL. Histones (A) and SIC or histone H4 (B) and SIC were preincubated for 1 h, and mixed with the wild-type bacteria for 1 h at 37°C. (C) S. pyogenes SIC mutant was prepared as described above. Histones and SIC were preincubated for 1 h, and mixed with the SIC mutant for 1 h at 37°C. Samples were diluted and plated on TH agar plates and CFU were determined the following day. Data show mean ± SEM (one-way ANOVA Dunnett’s test). (D) Erythrocytes were diluted to 5% (v/v) in PBS and incubated with histones and different concentrations of SIC for 1 h. Hemolysis was measured at 540 nm in supernatants after centrifugation, and was expressed as percentage of erythrocytes treated with 0.1% Triton X-100. Data show mean ± SEM (one-way ANOVA Dunnet’s test). All experiments were independently performed at least three times. *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.

**SIC Increasing Histone-Induced IL-6 Production via TLR4**

To investigate the target receptor of SIC/histone-induced cytokine production, we focused on IL-6. First, we confirmed, using blood from one donor, that SIC/histone-complexes can induce IL-6 production (Fig. 5A). Interestingly, the IL-6 production was amplified when the SIC concentration was increased (Fig. 5A). Then we repeated the experiment using several donors at the most potent SIC concentration (Fig. 5B). Our previous studies have shown that histones induce chemokine production by binding to the TLR4/MD-2 complex (16). To investigate whether this pathway is responsible for the enhancing effect, SIC and histones were added to human blood together with the TLR4-inhibitor CLI-095 or inhibitory antibodies against TLR4, TLR2, or an isotype control. Figures 5C,D depict that blocking the TLR4 response almost completely abrogated IL-6 production, suggesting that the interaction of SIC with extracellular histones can contribute to
the release of pathological levels of IL-6 involving an activation of the TLR4 signaling pathway.

To investigate whether the SIC-induced amplification of inflammation applies not only to histones, but also to other cationic SIC-binding AMPs, we incubated blood from healthy donors together with LL-37, β defensin-3, HMGB1, and HBP in the absence or presence of SIC. Subsequent Bioplex multiplex assays revealed that SIC boosted cytokine/chemokine production of LL-37, β defensin-3, and HMGB1, but had no effect on HBP (Figure S4 in Supplementary Material). These findings indicate that the pro-inflammatory property of SIC applies to several cationic AMPs, including histones, with important functions in the innate immune system.

**SIC and Extracellular Histones Present at the Infected Tissue Site in Patients with Necrotizing Soft-Tissue Infection**

*S. pyogenes* strains of the M1 serotype are among the most frequently identified serotypes isolated from patients with severe invasive infections including NSTI and toxic shock syndrome.

**FIGURE 4 | Continued**
We previously reported that in patients with NSTI, histones from necrotic cells are released into the extracellular compartments (16, 17). As invasive \textit{S. pyogenes} strains often belong to the M1 serotype and secrete large quantities of SIC under \textit{in vitro} conditions (7), we investigated whether SIC is released in NSTI patients, and if so, whether it is found to colocalize with histones.

To this end, tissue sections from biopsies of patients infected with \textit{S. pyogenes} M1 or M3 (a serotype negative for SIC) strains were analyzed with immunofluorescence staining. As shown in Table 2, we analyzed three biopsies that were positively stained for HMGB1, a marker for disease severity (33). All analyzed sections exhibited signs of inflammation (IL-8) and were colonized with...
**Figure 5** | SIC/histone complexes inducing IL-6 production via TLR4. (A) Heparinized blood was diluted 1:1 in PBS. Histones (50 µg/mL) and different concentrations of SIC were preincubated for 1 h and added to the blood. Samples were incubated for 7 h at 37°C and IL-6 was measured in the plasma SN. Data show mean ± SEM (n = 3). (B) Heparinized blood from six donors was investigated for IL-6 production after incubation with SIC/histone complexes for 7 h at 37°C. Data show mean ± SEM (one-way ANOVA, Tukey’s test). IL-6 production was measured in blood incubated with histones, SIC, and different concentrations of the TLR4 inhibitor CLI-095 (n = 3) (C) or anti-TLR4 antibodies (25 µg/mL) (n = 3), anti-TLR2 antibodies (25 µg/mL) (n = 3), or isotype control (25 µg/mL) (n = 3) (D). Values are expressed as fold increase to diluted blood stimulated with PBS. Data show mean ± SEM (one-way ANOVA, Tukey’s test). *P ≤ 0.05, **P ≤ 0.01, and ***P ≤ 0.001.

**Table 2** | Analysis of biopsies from patients with *S. pyogenes* necrotizing soft-tissue infections.

| Patient ID | M type | HMGB1 | IL-8 | GAS |
|------------|--------|-------|------|-----|
| 2001       | M1     | 30    | 51   | 24  |
| 2006       | M1     | 47    | 81   | 65  |
| 2028       | M3     | 57    | 65   | 51  |
| Healthy control | Negative | Negative | Negative | Negative |

Biopsies were stained with antibodies against high-mobility group (HMGB1), IL-8, and the Lancefield group-specific carbohydrate identifying group A Streptococcus (GAS), and the stainings were quantified using acquired computerized image analysis.

*S. pyogenes* (GAS). Moreover, a biopsy from a healthy donor was included with undetectable levels of HMGB1, IL-8, and *S. pyogenes*. The four biopsies were stained with antibodies against SIC (red) and histone H4 (green) as well as with the nuclear DNA stain DAPI (blue). Histone H4 was readily detected in tissue sections from both M1- and M3-infected patients, as well as in the biopsy from a healthy control (Figure S5 in Supplementary Material). SIC showed a strong staining in the M1-infected tissue (Figures 5A,B in Supplementary Material), whereas in the M3 only a background staining was noted (Figure 5C in Supplementary Material).
Moreover, we recorded a few areas of colocalization between SIC and histone H4 in the biopsy sections from M1 patients (Figures 6A, B), indicative of a potential SIC/histone H4 complex formation at the infected tissue site. Histone H4 but not SIC was detected in the biopsy from a healthy donor (Figure 6C; Figure 5D in Supplementary Material). Taken together, these findings demonstrate that SIC is expressed and released during *S. pyogenes* NSTI and that SIC is present in areas with extracellular histones and may form complexes at the infected tissue site of patients with NSTI. To conclude, our data show that SIC can form complexes with histones *in vitro*, and block histone-mediated effects on both bacterial and eukaryotic membranes. Furthermore, we found that SIC/histone complex formation synergistically increases a broad and potentially pathological inflammatory response in human blood. Lastly, we demonstrate that SIC is expressed in patients suffering from NSTI and that SIC partly colocalize with histones, suggesting that complex formation also occurs in patients with invasive streptococcal skin infections.

**DISCUSSION**

In the present study, we found that SIC can boost pro-inflammatory responses in human blood by forming complexes with histones. The streptococcal protein was initially recognized for its ability to inhibit the complement system by binding to the C5b–C9 complex, also known as the membrane attack complex, hence the name streptococcal inhibitor of complement (3). Although this interaction has been intensively studied, the pathophysiological role is not completely understood. Notably, *S. pyogenes* is resistant to complement-mediated lysis because of its thick peptidoglycan layer (4). These findings suggest that SIC may employ additional functions beyond blocking the complement system. For example, the extensive list of AMPs including extracellular histones constitutes another important group of SIC ligands. AMPs, such as LL-37 and defensins, are expressed by epithelial cells in the upper respiratory tract (34, 35). Despite this antimicrobial environment, *S. pyogenes* colonizes the pharynx of up to 30% of the population without being killed.

Within the last years, there have been a couple of studies showing that the interaction between SIC and host-derived proteins helps the bacteria to escape elimination by host defense systems. For instance, streptococcal survival in saliva is decreased when SIC-mutant strains are employed (36) and similar findings were published using a murine model of oropharyngeal infection (37). Based on these and other reports, we hypothesize that under these or other non-inflammatory conditions, SIC is needed to protect streptococci from an otherwise lethal immune attack. Thus, it seems that SIC helps to establish a non-inflammatory environment when the bacteria need to colonize and start to proliferate. However, under invasive conditions, SIC can contribute to the induction of systemic inflammatory reactions. For instance, SIC is upregulated when exposed to blood. Maximum levels of *sic* expression is detected already 30 min after its exposure to blood (38). It should be noted that SIC levels are increased together with other mga-regulated mediators such as fibronectin-binding proteins, collagen-like surface proteins, C5a peptidase, and M-proteins. Like SIC, these proteins can evoke pro-inflammatory
reaction which in concert can lead to life-threatening complica-
tions as, for instance, seen in patients suffering from streptococ-
cal necrotizing fasciitis. During these necrotic conditions, SIC
forms complexes with extracellular histones that in turn
induce cytokine production, thereby causing an overwhelming
and pathological inflammatory response. Using other danger
signals such as LL-37, β defensin-3, and HMGB1, we find similar
boosting activities of SIC (Figure 4 in Supplementary Material),
suggesting that the protein is a general enhancer of inflammatory
reactions once the immune system is alerted.

When testing different histone subclasses, we found that SIC
binds exclusively to histone H3 and H4, which shows a specific-
ity between the cationic histone subclasses. Our previous results
with TLR antagonists demonstrated that extracellular histones
alone can induce cytokine production through TLR4 on mono-
cytes and macrophages (16). Noteworthy, SIC/histone complexes
also induce IL-6 production through TLR4, suggesting that it
activates the receptor using the same molecular mechanisms.
In the same study, the cytokine-inducing residues of histone
H4 was mapped to amino acids 35–54 (IRR20) (16). This bind-
ing site is different from the SIC-binding region that we have
mapped to amino acids 1–20 (MSG20) of the N-terminal region
of histone H4. These findings suggest a plausible explanation
for how histone H4 can interact with SIC and simultaneously
activate TLR4.

Since the cationic N-terminal part of histone H4 is
responsible for the binding to SIC, the N-terminal parts of all
histone subclasses were compared. The segments spanning the
first 20 amino acids of histones H4 and H4 have both a net
charge of +7, mediated by three arginine residues and four
lysine residues. The corresponding sequences in H1 and H2B
have one or no lysine residue, respectively, and a net charge
of +4 (Table 3). Arginine is known to be cytotoxic to plasma
membranes, and this may be an evolutionary reason as to why
SIC has acquired affinity for H3 and H4 specifically. Though
histone H2A has the same distribution of arginine and lysine
residues and also a net charge of +7, it fails to interact with
SIC. This finding may also indicate that structural elements are
important for the interaction of SIC with histones. However,
more experimental support is needed to draw a conclusive
explanation for our results.

In order to cause inflammation SIC has to interact with host
proteins. This is in contrast to bacterial virulence factors which
exert their pathological activity by interacting directly with
their target receptor or cell. However, there are apart from SIC
also other important virulence determinants using a similar
approach. For example, LPS is using LPS-binding protein, a
soluble acute-phase protein, to elicit immune responses through
TLR4 (39). Streptococcal M-protein activates neutrophils by
forming complexes with fibrinogen, while M-protein-induced
TLR2 activation does not require fibrinogen (40). S. pyogenes and
Staphylococcus aureus release streptokinase and staphylokinase,
respectively, two enzymes that can activate plasminogen and help
the bacteria to disseminate from the site of infection (41) strep-
tokinase (42). These examples show the sophisticated adaption of
different pathogens to modulate the immune response and cause
pathologic conditions.

To summarize, our in vitro data reveal that SIC/histone
complexes elicit a broad upregulation of multiple pro-inflam-
matory cytokines, and it seems reasonable to speculate that
SIC/histone complexes are formed in vivo as well. This leads to
a cascade of events that amplifies inflammation and worsens
the outcome of the infection, although the complex formation
in vivo has to be further studied. Our study therefore shows
that SIC has a Janus-faced function as it, on one hand, dampens
the host reaction to infection, but on the other hand by its
interaction with danger signals trigger massive inflammatory
reactions.

ETHICS STATEMENT

The study was approved by the Institutional review board (IRB)
at the Lund University Hospital (Protocol no. 790/2005).

AUTHOR CONTRIBUTIONS

JW, LB, and HH conceived and designed the study. MM per-
formed and analyzed the experiments in Figure 2. BC, JS, AN,
and AN-T designed, performed, and analyzed colocalization
experiments. JW designed, performed, and analyzed all remaining
experiments, including Figures 1, 3, 4 and 5. I-MF purified SIC.
MM and OH collected biopsies from patients with NSTI. I-MF
and LB provided with intellectual content. JW and HH wrote the
manuscript. All authors reviewed the results and approved the
final version of the manuscript.

ACKNOWLEDGMENTS

We thank Maria Baumgarten, Ingrid Gustafsson, Pia Andersson,
and Sandra Jovic Tosovic for excellent technical assistance and
Christofer Karlsson for performing the mass spectrometry
analysis of SIC.

**TABLE 3** Alignment of the N-terminal of all histone subclasses.

| Protein | N-terminal sequence | Net charge | Arginines (R) | Lysines (K) |
|---------|---------------------|------------|---------------|-------------|
| Histone H1 | MTENSTSAPAAKPKRAKASIK | +4         | 1             | 4           |
| Histone H2A | MSGRGKGGKGGARAKAKPTRSS | +7         | 3             | 4           |
| Histone H2B | MPEPAAAPRGKGGKGGAKAHT | +4         | 0             | 5           |
| Histone H3.1 | MARTKQTARKSTGKGGAPKQK | +7         | 3             | 4           |
| Histone H4 | MSGRGKGGKGGKGGAKHRHR | +7         | 3             | 4           |

The first 20 amino acids of each histone are depicted below, together with their net charge, and their arginine- and lysine content.
FUNDING
This work was supported in part by the EMBO Long-Term Fellowship (grant number ALTF 18-2016 to JW), E and K.G. Lennander Foundation (to JW), Alfred Österlund Foundation (to HH and LB), the Knut and Alice Wallenberg Foundation (grant number 2011.0037 to HH and LB), the Medical Faculty at Lund University (to HH), the Swedish Foundation for Strategic Research (grant number SB12-0019 to HH), the Swedish Research Council (grant number 2016-01104 to HH and grant number K2014-58X-07480 to LB), the Torsten Söderberg Foundation (grant number M37/13 to LB), the Swedish Government Funds for Clinical Research (grant number ALFSKANE-431421 to LB), European Union (FP7/2007–2013) (grant number 305340 to AN-T and OH). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found online at http://www.frontiersin.org/articles/10.3389/fimmu.2018.00236/full#supplementary-material.

REFERENCES
1. Bisno AL, Brito MO, Collins CM. Molecular basis of group A streptococcal virulence. *Lancet Infect Dis* (2003) 3:191–200. doi:10.1016/S1473-3099(03)00576-0
2. Cole JN, Barnett TC, Nizet V, Walker MJ. Molecular insight into invasive group A streptococcal disease. *Nat Rev Microbiol* (2011) 9:724–36. doi:10.1038/nrmicro2648
3. Akesson P, Sjoholm AG, Bjorck L. Protein SIC, a novel extracellular protein of *Streptococcus pyogenes* interfering with complement function. *J Biol Chem* (1996) 271:1081–8. doi:10.1074/jbc.271.2.1081
4. Fernie-King BA, Seilly DJ, Willers C, Wurzner R, Davies A, Lachmann PJ. Streptococcal inhibitor of complement inhibitor (SIC) inhibits the membrane attack complex by preventing uptake of CS67 onto cell membranes. *Immunology* (2001) 103:390–0. doi:10.1046/j.1365-2567.2001.01249.x
5. Fernie-King BA, Seilly DJ, Lachmann PJ. The interaction of streptococcal inhibitor of complement (SIC) and its proteolytic fragments with the human beta defensins. *Immunology* (2004) 111:444–52. doi:10.1111/j.1365-2805.2004.01837.x
6. Frick IM, Shannon O, Akesson P, Morgelin M, Collin M, Schmidtschen A, et al. Antibacterial activity of the contact and complement systems is blocked by SIC, a protein secreted by *Streptococcus pyogenes*. *J Biol Chem* (2011) 286:1331–40. doi:10.1074/jbc.M110.178350
7. Frick IM, Akesson P, Rasmussen M, Schmidtschen A, Bjorck L, SIC, a secreted protein of *Streptococcus pyogenes* that inactivates antibacterial peptides. *J Biol Chem* (2003) 278:16561–6. doi:10.1074/jbc.M301995200
8. Pence MA, Rooijakkers SH, Cogen AL, Cole JN, Hollands A, Gallo RL, et al. Streptococcal inhibitor of complement promotes innate immune resistance phenotypes of invasive M1T1 group A Streptococcus. *J Innate Immun* (2010) 2:2587–99. doi:10.1159/000317672
9. Fernie-King BA, Seilly DJ, Davies A, Lachmann PJ. Streptococcal inhibitor of complement inhibits two additional components of the mucosal innate immune system: secretory leukocyte protease inhibitor and lysozyme. * Infect Immun* (2002) 70:4908–16. doi:10.1128/IAI.70.9.4908-4916.2002
10. Akesson P, Herwald H, Rasmussen M, Hakansson K, Abrahamsson M, Hasan AA, et al. Streptococcal inhibitor of complement-mediated lysis (SIC): an anti-inflammatory virulence determinant. *Microbiology* (2010) 156:3660–8. doi:10.1099/mic.0.039578-0
11. Hmondsor ER, McVver KS. The Mga virulence regulon: infection where the grass is greener. * Mol Microbiol* (2007) 66:1056–65. doi:10.1111/j.1365-2958.2007.06006.x
12. Binks MJ, Fernie-King BA, Seilly DJ, Lachmann PJ, Sriprakash KS. Attribution of the various inhibitory actions of the streptococcal inhibitor of complement (SIC) to regions within the molecule. *J Biol Chem* (2005) 280:20120–5. doi:10.1074/jbc.M414194200
13. Oehmcke S, Morgelin M, Herwald H. Activation of the human contact system on neutrophil extracellular traps. *J Innate Immun* (2009) 1:225–30. doi:10.1159/000192030
14. Knight JS, Carmona-Rivera C, Kaplan MJ. Proteins derived from neutrophil extracellular traps may serve as self-antigens and mediate organ damage in autoimmune diseases. *Front Immunol* (2012) 3:380. doi:10.3389/fimmu.2012.00380
15. Xu J, Zhang X, Monestier M, Esmon NL, Esmon CT. Extracellular histones are mediators of death through TLR2 and TLR4 in mouse fatal liver injury. *J Immunol* (2011) 187:2626–31. doi:10.4049/jimmunol.1003930
16. Westman J, Papareddy P, Dahlgren MW, Chakrakodi B, Norby-Teglund A, Smeds E, et al. Extracellular histones induce chemokine production in whole blood ex vivo and leukocyte recruitment in vivo. *PLoS Pathog* (2015) 11:e1005319
17. Westman J, Smeds E, Johansson L, Morgelin M, Olin AL, Malmstrom E, et al. Treatment with p33 curtails morbidity and mortality in a histone-induced murine shock model. *J Innate Immun* (2014) 6:819–30. doi:10.1159/000363348
18. Xu J, Zhang XM, Pelayo R, Monestier M, Ammollo CT, Semeraro F, et al. Extracellular histones are major mediators of death in sepsis. *Nat Med* (2009) 15:1318–21. doi:10.1038/nm.2053
19. Fuchs TA, Bhardari AA, Wagner DD. Histones induce rapid and profound thrombocytopenia in mice. *Blood* (2011) 118:3708–14. doi:10.1182/blood-2011-03-332676
20. Huang H, Chen HW, Evankovich J, Yan W, Rosborough BR, Nace GW, et al. Histones activate the NLRP3 inflammasome in Kupffer cells during sterile inflammatory liver injury. *J Immunol* (2013) 191:2665–70. doi:10.4049/jimmunol.1202733
21. Semeraro F, Ammollo CT, Morrissey JH, Dale GL, Friese P, Esmon NL, et al. Extracellular histones promote thrombin generation through platelet-dependent mechanisms: involvement of platelet TLR2 and TLR4. *Blood* (2011) 118:1952–61. doi:10.1182/blood-2011-03-343061
22. Hirsch JG. Bacterial action of histone. *J Exp Med* (1958) 108:925–44. doi:10.1083/jem.108.6.925
23. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* (1970) 227:680–5. doi:10.1038/227680a0
24. Bober M, Enochsson C, Collin M, Morgelin M. Collagen VI is a subepithelial adhesive target for human respiratory tract pathogens. *J Innate Immun* (2010) 2:160–6. doi:10.1159/000233587
25. Baschong W, Wrigley NG. Small colloidal gold conjugated to Fab fragments or to immunoglobulin G as high-resolution labels for electron microscopy: a technical overview. *J Electron Microsc Tech* (1990) 14:313–23. doi:10.1002/jemt.16601405
26. Thulin P, Johansson L, Low DE, Gan BS, Koth M, McGeer A, et al. Viable group A streptococci in macrophages during acute soft tissue infection. *PLoS Med* (2006) 3:e53. doi:10.1371/journal.pmed.0030053
27. Siemens N, Kittang BR, Chakrakodi B, Oppegaard O, Johansson L, Bruun T, et al. Increased cytotoxicity and streptolysin O activity in group G streptococcal strains causing invasive tissue infections. *Sci Rep* (2015) 5:16945. doi:10.1038/srep16945
28. Johansson L, Linner A, Sunden-Cullberg J, Haggar A, Herwald H, Lore K, et al. Neutrophil-derived hyperresistinemia in severe acute streptococcal infections. *J Immunol* (2009) 183:4047–54. doi:10.4049/jimmunol.0901541
29. Semeraro F, Ammollo CT, Esmon NL, Esmon CT. Histones induce phosphatidylserine exposure and a procoagulant phenotype in human red blood cells. J Thromb Haemost (2014) 12:1697–702. doi:10.1111/jth.12677
30. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature (2002) 415:389–95. doi:10.1038/415389a
31. Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol (2003) 3:710–20. doi:10.1038/nri1180
32. Cunningham MW. Pathogenesis of group A streptococcal infections. Clin Microbiol Rev (2000) 13:470–511. doi:10.1128/CMR.13.3.470-511.2000
33. Johansson L, Snall J, Sendi P, Thulin P, Linder A, et al. HMGB1 in severe soft tissue infections caused by Streptococcus pyogenes. Front Cell Infect Microbiol (2014) 4:1. doi:10.3389/fcimb.2014.00004
34. Durr UH, Sudheendra US, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta (2006) 1758:1408–25. doi:10.1016/j.bbamem.2006.03.030
35. O’Neil DA, Porter EM, Elewaut D, Anderson GM, Eckmann L, Ganz T, et al. Expression and regulation of the human beta-defensins hBD-1 and hBD-2 in intestinal epithelium. J Immunol (1999) 163:6718–24.
36. Shelburne SA III, Granville C, Tokuyama M, Sitkiewicz I, Patil P, Musser JM. Growth characteristics of and virulence factor production by group A Streptococcus during cultivation in human saliva. Infect Immun (2005) 73:4723–31. doi:10.1128/IAI.73.8.4723-4731.2005
37. Lukomski S, Montgomery CA, Rurangirwa J, Geske RS, Barrish JP, Adams GJ, et al. Extracellular cysteine protease produced by Streptococcus pyogenes participates in the pathogenesis of invasive skin infection and dissemination in mice. Infect Immun (1999) 67:1779–88.
38. Graham MR, Virtanena K, Porcella SF, Barry WT, Gowen BB, Johnson CR, et al. Group A Streptococcus transcriptome dynamics during growth in human blood reveals bacterial adaptive and survival strategies. Am J Pathol (2005) 166:455–65. doi:10.1016/S0002-9440(10)62268-7
39. Fujihara M, Murui M, Tanamoto K, Suzuki T, Azuma H, Ikeda H. Molecular mechanisms of macrophage activation and deactivation by lipopolysaccharide: roles of the receptor complex. Pharmacol Ther (2003) 100:171–94. doi:10.1016/j.pharmthera.2003.08.003
40. Herwald H, Cramer H, Morgelin M, Russell W, Sollenberg U, Norrby-Teglund A, et al. M protein, a classical bacterial virulence determinant, forms complexes with fibrinogen that induce vascular leakage. Cell (2004) 116:367–79. doi:10.1016/S0092-8674(04)00057-1
41. Collier D, Lijnen HR. Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? Blood (1994) 84:680–6.
42. Young KC, Shi GY, Wu DH, Chang LC, Chang BI, Ou CP, et al. Plasminogen activation by streptokinase via a unique mechanism. J Biol Chem (1998) 273:3110–6. doi:10.1074/jbc.273.5.3110

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.